Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expired OTCs, formula cost Walmart $775,000 in N.J.

This article was originally published in The Tan Sheet

Executive Summary

Walmart agrees to pay $775,000 and revise its practices to comply with New Jersey laws after a judge finds the firm sold expired infant formula and nonprescription drugs. The state court ruling found the N.J. Office of the Attorney General proved four of the eight counts in a 2008 lawsuit, including that Walmart sold items at incorrect prices, the AG said Oct. 19. The remaining counts, for questionable business practices and other violations, are to be decided in a trial in Hudson County. Under the settlement, the firm will pay $500,000 in penalties, reimburse the state $160,000 for legal expenses and $40,000 for investigative costs, and pay $75,000 for a consumer education initiative. The settlement requires Walmart to periodically inspect OTC drugs and infant formula and monitor merchandise price accuracy at New Jersey stores. Walmart admitted no wrongdoing in the settlement that supersedes a 2004 consent order the firm and state made to resolve similar issues

You may also be interested in...



Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

Novartis Holds Out For Happier Second Half Of 2020

The fourth quarter proved to be challenging for Novartis, with its dermatology, ophthalmology and oncology products – and Zolgensma – feeling the impact of COVID-19 lockdowns. The company is hoping for much better things in the second part of 2021.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel